Vol 25, No 6 (2020)
Original research articles
Published online: 2020-11-01

open access

Page views 344
Article views/downloads 474
Get Citation

Connect on Social Media

Connect on Social Media

Serum cytokine profile as a potential prognostic tool in colorectal cancer patients – one center study

Paulina Czajka-Francuz1, Tomasz Francuz2, Sylwia Cisoń-Jurek1, Aleksander Czajka3, Marcin Fajkis1, Bożena Szymczak1, Maciej Kozaczka4, Krzysztof Piotr Malinowski5, Wojciech Zasada6, Jerzy Wojnar1, Jerzy Chudek1
DOI: 10.1016/j.rpor.2020.08.004
Rep Pract Oncol Radiother 2020;25(6):867-875.



Comparison of 14 cytokines levels between a control group and prospectively enrolled CRC patients to confirm their significance in CRC development. We tested if a model based on 14 cytokines levels could predict prognosis in Caucasian CRC patients treated with 5-FU based chemotherapy.


Novel prognostic tools in colorectal cancer (CRC) are necessary to optimize treatment, reduce toxicity and chemotherapy (CHT) costs.

Materials and Methods

We assessed prognostic significance of 14 cytokines: IL-1 beta, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL-17A in 75 prospectively enrolled CRC patients before initiation of palliative or adjuvant CHT and in 22 control subjects. Readings were taken using the Bio-Plex 200 System. Response to treatment was assessed after 6 months from initiation of CHT. The treated group was divided depending on the response into a progressors (death, progression of disease) and non-progressors group (stable disease, partial response, complete response).


We found that increased concentration of IL-8 was a negative prognostic factor in the whole group and palliative subgroup, whereas increased level of IL-10, IL-7, and IL-12p70 was a negative predictor in the adjuvant group CHT.


We proposed a statistical model based on circulating cytokine levels, showing a good prognostic value in prediction of the response to CHT (AUC = 0.956). The model, including combined IL-2, IL-8, IL-10 and IL-13 levels, established in the whole treated group, should be validated in larger trials.

Article available in PDF format

View PDF Download PDF file

Reports of Practical Oncology and Radiotherapy